Apellis Pharmaceuticals Inc Stock Forecast:
According to 12 analysts’ predictions for Apellis Pharmaceuticals Inc, the average expected price for the company’s stock over the next 12 months is USD 77.72, and the analysts have rated the stock as a “Strong Buy.” However, Stock Target Advisor’s analysis of the stock is “Bearish,” based on 2 positive signals and 6 negative signals. As of the last closing, the stock was trading at USD 55.49, which represents an increase of 6.90% over the past week, 6.61% over the past month, and 29.86% over the last year.
Analysts Coverage Change:
- Citigroup maintains (APLS:NSD). with a “Buy” rating and raises the price target to $90 from $86.
- Needham & Company reiterates the “Buy” rating and raises the price target to $80 from $70.
- H.C. Wainwright reiterates the “Buy” rating and maintains a price target of $87.
- Stifel Nicolaus maintains a “Buy” rating and raises the price target to $75 from $65.
- Robert W. Baird & Co. maintains the “Outperform” rating for Apellis Pharma and raises the price target to $105 from $90.
Apellis Pharmaceuticals News:
On Friday, the Nasdaq halted trading of Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares after they increased by 6.95%. This was due to the Food and Drug Administration approving the company’s Syfovre drug, which is used to treat geographic atrophy (GA) resulting from age-related macular degeneration, an eye disease. Apellis Pharmaceuticals Inc stated that Syfovre is the first and only FDA-approved treatment for GA, which is a significant cause of blindness affecting over one million people in the U.S. and five million people globally.
Positive Fundamentals:
Apellis Pharmaceuticals Inc. is a company with a high market capitalization, meaning it has a large valuation relative to other companies in its sector. Companies with a high market capitalization are generally considered more stable, as they have the resources and scale to weather market fluctuations.
In addition to having a high market capitalization, Apellis Pharmaceuticals has also delivered superior risk-adjusted returns. Risk-adjusted returns refer to the amount of return a company generates for each unit of risk it takes on. Apellis Pharmaceuticals has performed well on this metric when compared to its peers in the same sector, placing it in the top quartile of performers.
It’s important to note that these metrics are based on a hold period of at least 12 months. This means that investors who hold Apellis Pharmaceuticals stock for at least a year have historically been rewarded with strong returns relative to the amount of risk they took on.
Negative Fundamentals:
Apellis Pharmaceuticals Inc. is a highly volatile stock with total returns that have been volatile and above the median for its sector over the past five years. This means that investing in this stock requires a higher risk tolerance as the price of the stock is subject to fluctuations.
On a price-to-book value basis, Apellis Pharmaceuticals is overpriced compared to its peers, which indicates that the market is willing to pay more for the company’s assets than its competitors. This may be due to high growth expectations or positive news about the company’s future prospects.
The company is highly leveraged, which means that it has a high level of debt relative to its equity. However, it is important to check the news and management statements, as this high level of leverage could be a result of the company’s aggressive growth strategy.
In the most recent four quarters, Apellis Pharmaceuticals had negative total cash flow and negative total free cash flow, which means that the company had more cash going out than coming in. This is a concerning sign for investors, as the company may have difficulty funding its operations and growth in the future.
Finally, Apellis Pharmaceuticals has shown below median earnings growth in the previous five years compared to its sector. This means that the company has not been as successful in generating profits as its peers, which may be a red flag for investors.
FA Score (Fundamental Analysis):
The fundamental analysis of Apellis Pharmaceuticals is “Bearish” with a FA score of 2.5 out of 10, where 0 is very bearish and 10 is very bullish.
